Skip to main
SRRK
SRRK logo

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding Corp's stock exhibits a positive outlook supported by a recent 4% increase in share value, which reflects favorable market sentiment regarding the company's Phase 3 SAPPHIRE trial results. The stock is currently perceived as undervalued, trading at approximately 14 times net cash, indicating a favorable risk/reward profile over the next 12 to 24 months. Additionally, the successful resolution of regulatory observations at the contract development and manufacturing organization (CDMO) facility reinforces management's confidence in advancing their drug substance production and potential expedited regulatory approval.

Bears say

Scholar Rock Holding Corp is facing significant delays in the commercial launch of its lead product, apitegromab, now pushed back to 2026 in the US and 2026 in the EU, affecting peak sales estimates which have been reduced to $1.7 billion by 2035. The recent issuance of a Complete Response Letter (CRL) not only stalls the launch but also introduces increased regulatory hurdles and competitive risks associated with apitegromab, particularly in spinal muscular atrophy (SMA) and other indications. Additionally, the ongoing challenges with SRK-181 targeting TGFβ raise concerns about the drug's risk/benefit profile and the company's ability to navigate a competitive landscape, further contributing to a negative outlook on its stock.

SRRK has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 9 analysts, SRRK has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.